XCancer

A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT

Description:

Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.

Sponsor:

Second Affiliated Hospital of Guangzhou Medical University

Contacts:

HAO PENG (CONTACT)

1194171163@qq.com

0086-13544443827

Rusen Zhang (CONTACT)

zhangrusen2015@163.com

0086-13642328295

Government Study Link:

NCT07602569 - Click here to see study on

ClinicalTrials.gov

FGln

Isotope(s):
Target(s):
  • Glutaminolytic Activity
Ligand Class: Small Molecules
Inclusion
  • Patients with clinical suspicion or exclusion of primary or recurrent malignant tumors (such as glioma of the brain, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer, etc., where 18F-FDG is prone to false negatives and false positives)
  • Patients without other tumor history
  • Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET/CT or 18F-FGln PET/CT to determine the most appropriate treatment strategy
Exclusion
  • other situations where the investigators consider it inappropriate for the subjects to participate in this clinical trial
  • patients with poor compliance, unable to tolerate or cooperate with PET/CT examinations.
  • those who have undergone gastrointestinal barium meal examination within one week;